Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight
NCT ID: NCT00584519
Last Updated: 2021-02-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
430 participants
OBSERVATIONAL
2007-06-30
2009-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To analyse the perceived health status and the level of functioning and disability of patients with schizophrenia and overweight and their progress at 3, 6 and 12 months.
To assess the progress of the symptoms of the disease at 6 and 12 months.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevalence of the Metabolic Syndrome in SPR Taking Antipsychotics
NCT00569504
Risk Prediction Model of Cardiovascular Events in Patients With Schizophrenia
NCT05498571
Prevalence of Metabolic Syndrome in Patients With Schizophrenia in Korea
NCT01477918
Direct Measurements of Cardiometabolic Risk in Treated Schizophrenia Patients
NCT00501163
The Prevalence of Obesity For Schizophrenia Inpatients in Taiwan
NCT01170689
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
500 patients
Patients with diagnosis of schizophrenia, schizophreniform or schizoaffective disorder (DSM-IV TR) with BMI (body mass index) more or equal to 25 Kg/m2
non-interventional
non-interventional
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
non-interventional
non-interventional
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with BMI (body mass index) more or equal to 25 Kg/m2
* Patients or their legal representative have provided written informed consent
Exclusion Criteria
* Patients are currently enrolled on clinical trials or other investigational studies
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A1281162
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.